Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with infliximab and methotrexate

Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with infliximab and methotrexate - Combination therapy with Methotrexate, Infliximab, and Tacrolimus (COMMIT project)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000512

Enrollment

Registered

2006-11-03

Start date

2006-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

If the score of DAS28 is under 3.2 in rheumatoid arthritis patients who have received infliximab and methotrexate, doses of methotrexate will reduced to 2mg/w. When the score of DAS28 increses, tacrol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Rheumatoid arthritis patients who have been treated with methotrexate and infliximab for over 22 weeks

Exclusion criteria

Exclusion criteria: Dose of predonisone is over 5mg/day, patients who cannot receive tacrolimus

Design outcomes

Primary

Measure	Time frame
DAS28	—

Secondary

Measure	Time frame
ACR definition of improvement, CRP, Adverse events	—

Countries

Japan

Contacts

Public ContactYuko Sugioka

Osaka City University Medical School Orthopaedic Surgery

tatsuya@med.osaka-cu.ac.jp06-6645-3851

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026